Barclays PLC Invests $497,000 in CeriBell (NASDAQ:CBLL)

Barclays PLC acquired a new position in CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 19,190 shares of the company's stock, valued at approximately $497,000. Barclays PLC owned 0.05% of CeriBell as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. FMR LLC bought a new stake in CeriBell during the 4th quarter worth approximately $128,120,000. Vanguard Group Inc. bought a new stake in shares of CeriBell during the fourth quarter valued at approximately $18,015,000. Board of Trustees of The Leland Stanford Junior University bought a new stake in shares of CeriBell during the fourth quarter valued at approximately $16,143,000. Franklin Resources Inc. bought a new stake in CeriBell in the fourth quarter worth $12,460,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in CeriBell during the fourth quarter valued at $10,750,000.

Insider Buying and Selling at CeriBell

In other news, CEO Xingjuan Chao sold 15,628 shares of the company's stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total value of $236,139.08. Following the completion of the sale, the chief executive officer now owns 727,151 shares of the company's stock, valued at approximately $10,987,251.61. This represents a 2.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 24,700 shares of company stock valued at $372,434 in the last three months.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 target price on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH assumed coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell has a consensus rating of "Buy" and an average target price of $32.50.

CeriBell Trading Up 7.5%

NASDAQ:CBLL traded up $1.19 during mid-day trading on Monday, hitting $17.16. 445,087 shares of the stock traded hands, compared to its average volume of 274,129. CeriBell has a 52 week low of $10.01 and a 52 week high of $32.75. The stock has a 50 day moving average price of $18.06.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. As a group, equities analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.